Document Detail


Clinical pharmacist impact on care, length of stay, and cost in pediatric cystic fibrosis (CF) patients.
MedLine Citation:
PMID:  23281228     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
BACKGROUND: Cystic fibrosis (CF) patients are often treated with aminoglycoside (AG) antibiotics during infective pulmonary exacerbations. Achieving pharmacokinetic and pharmacodynamic (PK/PD) targets to improve outcomes and counteract resistance is paramount. PURPOSE: The primary objective was to compare the number of pediatric CF patients achieving AG PK/PD targets when a clinical pharmacist (CP) managed therapeutic drug monitoring (TDM) compared with usual care (UC). METHODS: A retrospective cohort study was conducted on the records of 40 CF patients that received AGs and ≥2 serum samples between 1/2007 and 5/2009. Chi-square and Student's t-test were used to analyze nominal and continuous variables, respectively. RESULTS: Twenty-nine patients with 52 courses of AGs were included the CP group, and 22 patients with 42 courses were included the UC group. Ninety-eight percent of patients in the CP group reached AG PK/PD targets compared with 71% in the UC group, P < 0.001. Patients in the CP group reached the AG PK/PD target in a mean of 1.9 ± 0.8 days compared with 4.8 ± 3.4 days in the UC group, P < 0.0001. The average LOS in the CP group was 9 ± 5 days compared with 12 ± 7.5 days in the UC group, P = 0.033. The mean number of levels per patient was 2.7 in the CP group compared with 5.2 (range of 2-20) in the UC group, P < 0.001. Resource utilization associated with drug levels, dosing adjustments and LOS were $26,549, $14,069, and $1,680,000 in the CP group as compared with $40,683, $27,812, and $1,940,000, respectively, in the UC group. CONCLUSION: CP managed TDM resulted in a significantly higher percentage of pediatric CF patients achieving AG PK/PD targets 3 days sooner with an average LOS that was 3 days shorter. CP managed TDM resulted in significantly fewer dosage adjustments, drug levels, and cost associated with serum sampling, drug wastage, and LOS. Pediatr Pulmonol. © 2012 Wiley Periodicals, Inc.
Authors:
Jeffrey J Cies; Laurie Varlotta
Related Documents :
23061598 - Switching to raltegravir in virologically suppressed in hiv-1-infected patients: a retr...
16517388 - Postoperative delirium in spine surgery.
23441068 - One-year head to head comparison of the neointimal response between sirolimus eluting s...
24076968 - Extraordinary heterogeneity of virological outcomes in patients receiving haart and mon...
20225978 - Evaluation of outcomes in dogs treated for pyothorax: 46 cases (1983-2001).
24928268 - Impact of complications and hospital-free days following radical cystectomy on health-r...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-12-31
Journal Detail:
Title:  Pediatric pulmonology     Volume:  -     ISSN:  1099-0496     ISO Abbreviation:  Pediatr. Pulmonol.     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2013-1-2     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8510590     Medline TA:  Pediatr Pulmonol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2012 Wiley Periodicals, Inc.
Affiliation:
St. Christopher's Hospital for Children, Philadelphia, Pennsylvania; Drexel University College of Medicine, Philadelphia, Pennsylvania. jeffrey.cies@gmail.com.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Synthesis of Various Saturated and Unsaturated N-Heterocyclic Carbene Precursors by Triflic Anhydrid...
Next Document:  Different toxic and hormetic responses of Bombus impatiens to Beauveria bassiana, Bacillus subtilis ...